Abstract
The response to the MAOI isocarboxazid was investigated in a two-phase protocol. Phase 1 was a double-blind, placebo-controlled study; Phase 2 was an open active medication trial for Phase 1 placebo patients who still met symptom criteria. In Phase 1, 60 male outpatients were randomly divided into placebo or active medication groups. Mean platelet MAO inhibition was 86% by Week 1, while significant symptomatic improvement was not seen until Week 3. In Phase 2, 16 of the symptomatic placebo patients were given an open trial on isocarboxazid; thus, 43 patients received a trial of active medication. Separation of responders (N=26) from nonresponders (N=17) by discriminant function analysis using 3 entry variables (platelet MAO activity, standing diastolic blood pressure, and psychomotor irregularity) accounted for 28% of the variance, with correct classification of 32 of the 43 patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 44-48 |
| Number of pages | 5 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 45 |
| Issue number | 7 II |
| State | Published - 1984 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
- Clinical Psychology
Cite this
Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. / Giller, E.; Bialos, D. D.; Harkness, L.; Riddle, Mark A.
In: Journal of Clinical Psychiatry, Vol. 45, No. 7 II, 1984, p. 44-48.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid
AU - Giller, E.
AU - Bialos, D. D.
AU - Harkness, L.
AU - Riddle, Mark A
PY - 1984
Y1 - 1984
N2 - The response to the MAOI isocarboxazid was investigated in a two-phase protocol. Phase 1 was a double-blind, placebo-controlled study; Phase 2 was an open active medication trial for Phase 1 placebo patients who still met symptom criteria. In Phase 1, 60 male outpatients were randomly divided into placebo or active medication groups. Mean platelet MAO inhibition was 86% by Week 1, while significant symptomatic improvement was not seen until Week 3. In Phase 2, 16 of the symptomatic placebo patients were given an open trial on isocarboxazid; thus, 43 patients received a trial of active medication. Separation of responders (N=26) from nonresponders (N=17) by discriminant function analysis using 3 entry variables (platelet MAO activity, standing diastolic blood pressure, and psychomotor irregularity) accounted for 28% of the variance, with correct classification of 32 of the 43 patients.
AB - The response to the MAOI isocarboxazid was investigated in a two-phase protocol. Phase 1 was a double-blind, placebo-controlled study; Phase 2 was an open active medication trial for Phase 1 placebo patients who still met symptom criteria. In Phase 1, 60 male outpatients were randomly divided into placebo or active medication groups. Mean platelet MAO inhibition was 86% by Week 1, while significant symptomatic improvement was not seen until Week 3. In Phase 2, 16 of the symptomatic placebo patients were given an open trial on isocarboxazid; thus, 43 patients received a trial of active medication. Separation of responders (N=26) from nonresponders (N=17) by discriminant function analysis using 3 entry variables (platelet MAO activity, standing diastolic blood pressure, and psychomotor irregularity) accounted for 28% of the variance, with correct classification of 32 of the 43 patients.
UR - http://www.scopus.com/inward/record.url?scp=0021254721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021254721&partnerID=8YFLogxK
M3 - Article
C2 - 6376484
AN - SCOPUS:0021254721
VL - 45
SP - 44
EP - 48
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
SN - 0160-6689
IS - 7 II
ER -